DARE
$1.45
Daré Bioscience, Inc.
Recent News
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Dare Bioscience Inc (DARE) outlines its innovative pipeline progress and financial fortification, while navigating regulatory hurdles and market expansion plans.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?